Retour
45
41
25
Fourchette du Jour
18,61 €
18,61 €
Fourchette 52 Semaines
8,62 €
20,78 €
Volume
200
Moyenne 50J / 200J
17,91 €
/
13,07 €
Clôture Précédente
18,53 €
Historique des Prix
Tendances Financières
Comparaison Sectorielle
vs médiane du secteur Healthcare (626 pairs)
| Métrique | Action | Médiane du Secteur |
|---|---|---|
| P/E | 18,2 | 0,4 |
| P/B | 4,7 | 2,9 |
| ROE % | 38,8 | 3,8 |
| Net Margin % | 5,8 | 3,9 |
| Rev Growth 5Y % | 9,2 | 10,0 |
| D/E | 0,9 | 0,2 |
Points Clés
Revenue grew 9,19% annually over 5 years — modest growth
Earnings grew 28,41% over the past year
ROE of 38,83% indicates high profitability
Generating 63,35M in free cash flow
PEG of 0,83 suggests growth is underpriced
Revenue growth is accelerating — 1Y growth exceeds 5Y average by 3,96%
Croissance
Revenue Growth (5Y)
9,19%
Revenue (1Y)13,15%
Earnings (1Y)28,41%
FCF Growth (3Y)N/A
Qualité
Return on Equity
38,83%
ROIC14,49%
Net Margin5,82%
Op. Margin8,33%
Sécurité
Debt / Equity
0,92
Current Ratio1,37
Interest Coverage7,20
Valorisation
P/E Ratio
18,20
P/B Ratio4,71
EV/EBITDA12,67
Dividend Yield0,02%
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | 13,15% | Revenue Growth (3Y) | 12,75% |
| Earnings Growth (1Y) | 28,41% | Earnings Growth (3Y) | 68,58% |
| Revenue Growth (5Y) | 9,19% | Earnings Growth (5Y) | 70,22% |
| Profitability | |||
| Revenue (TTM) | 1,66B | Net Income (TTM) | 96,58M |
| ROE | 38,83% | ROA | 9,06% |
| Gross Margin | 12,02% | Operating Margin | 8,33% |
| Net Margin | 5,82% | Free Cash Flow (TTM) | 63,35M |
| ROIC | 14,49% | FCF Growth (3Y) | N/A |
| Safety | |||
| Debt / Equity | 0,92 | Current Ratio | 1,37 |
| Interest Coverage | 7,20 | Dividend Yield | 0,02% |
| Valuation | |||
| P/E Ratio | 18,20 | P/B Ratio | 4,71 |
| P/S Ratio | 1,06 | PEG Ratio | 0,83 |
| EV/EBITDA | 12,67 | Dividend Yield | 0,02% |
| Market Cap | 1,76B | Enterprise Value | 1,75B |
Income Statement
Annual, most recent first
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 1,66B | 1,47B | 1,30B | 1,22B | 1,17B |
| Net Income | 96,58M | 75,21M | 33,98M | 69,55M | 11,50M |
| EPS (Diluted) | 1,11 | 0,86 | 0,40 | -0,05 | 0,11 |
| Gross Profit | 199,43M | 1,47B | 167,62M | 76,83M | 115,61M |
| Operating Income | 138,25M | 111,21M | 111,79M | 20,99M | 63,18M |
Balance Sheet
Annual, most recent first
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Total Assets | 1,07B | 719,79M | 672,73M | 781,58M | 900,32M |
| Total Liabilities | 692,58M | 595,44M | 584,81M | 680,88M | 798,40M |
| Shareholders' Equity | 373,07M | 124,35M | 87,92M | 100,70M | 101,92M |
| Total Debt | 342,65M | 292,49M | 334,52M | 383,97M | 536,85M |
| Cash & Equivalents | 348,90M | 121,85M | 75,18M | 167,28M | 104,63M |
| Current Assets | 451,57M | 243,70M | 187,14M | 258,04M | 224,92M |
| Current Liabilities | 329,91M | 292,88M | 226,39M | 274,99M | 281,91M |
Scores de Stratégies
This stock passed the criteria for 3 strategies
Score = fit strength (0–100)
Rank = position among all matches
Growth + Value
Growth at a Reasonable Price (Peter Lynch)
#205 of 326
Custom
Balanced Risk
#106 of 148
Custom
Lower Risk
#131 of 136
Activité Récente
Entré
Growth at a Reasonable Price (Peter Lynch)
Mar 24, 2026
Entré
Balanced Risk
Mar 24, 2026
Entré
Lower Risk
Mar 24, 2026